free
radic
reaction
play
import
role
biolog
function
live
system
balanc
prooxid
antioxid
necessari
normal
homeostasi
cell
organ
oxid
stress
play
import
role
mani
patholog
process
includ
viral
infect
influenza
excess
reactiv
oxygen
speci
ro
caus
oxid
damag
lipid
membran
mitochondri
respiratori
chain
mitochondria
act
platform
antivir
innat
immun
mitochondri
antivir
signal
involv
activ
retino
acidinduc
gene
ilik
receptor
requir
oxid
phosphoryl
activ
cell
respiratori
defect
exhibit
sever
impair
virusinduc
induct
interferon
proinflammatori
cytokin
mice
respiratori
chain
defect
highli
suscept
viral
infect
exhibit
signific
lung
inflamm
oxid
nitros
stress
may
also
contribut
reduc
antivir
immun
alter
axi
well
contribut
mechan
inflammatori
reaction
via
increas
nfkappab
augment
turnov
rate
thymocyt
cell
via
upregul
hand
antivir
drug
may
exhibit
genotox
effect
result
excess
product
reactiv
oxygen
speci
ro
therefor
antivir
drug
antioxid
potenti
would
protect
cell
inhibit
lipid
peroxid
andor
prevent
oxid
damag
mitochondri
respiratori
chain
antivir
function
antioxid
might
also
involv
modul
multipl
signal
pathwaystarget
use
viral
replic
fact
mani
effici
antioxid
exhibit
potent
antivir
effect
effici
antivir
drug
increas
combin
antioxid
exampl
vitro
synergist
antivir
effect
interferon
combin
unithiol
variou
variant
herp
simplex
demonstr
mixtur
echinochrom
ascorb
acid
alphatocopherol
show
higher
antioxid
antivir
effect
echinochrom
intraperiton
inject
natur
antioxid
silymarin
mice
neutral
genotox
effect
ribavirin
toward
mitochondri
dna
silymarin
also
exhibit
potent
antivir
activ
mayaro
viru
reduc
level
malondialdehyd
carbonyl
protein
biomark
oxid
stress
influenza
often
caus
pneumonia
viru
damag
epitheli
cell
low
respiratori
tract
due
viral
replic
columnar
ciliari
epithelium
lung
lead
progress
damag
alveolar
cell
bronchopneumonia
viral
combin
viralbacteri
massiv
bronchiti
reactiv
oxygen
speci
rosproduc
nadph
oxidas
relev
virusinduc
epitheli
apoptosi
lung
injuri
combin
antivir
drug
pyransod
conjug
reduc
ro
product
alveolar
macrophag
influenzainfect
mice
dramat
protect
anim
death
sum
oxid
balanc
critic
maintain
normal
function
host
wherea
oxid
stress
caus
viru
affect
intracellular
redox
balanc
lead
signific
chang
defens
system
provid
therapeut
option
prevent
control
viru
infect
antivir
drug
character
pro
antioxid
activ
affect
therapeut
effici
umifenovir
ethyl
dimethylamino
methyl
phenylsulfanyl
methyl
oral
antivir
drug
licens
treatment
prophylaxi
influenza
b
viru
infect
russia
ojsc
pharmstandardleksredstva
china
umifenovir
rapidli
absorb
distribut
organ
tissu
maximum
concentr
blood
plasma
administr
singl
dose
mg
ngml
approxim
umifenovir
interact
hemagglutinin
ha
protein
influenza
virus
stabil
low
ph
transit
fusogen
state
inhibit
hamedi
membran
fusion
influenza
viru
infect
antivir
activ
umifenovir
shown
vitro
vivo
differ
virus
includ
influenza
type
b
well
acut
respiratori
tract
infect
agent
adenoviru
respiratori
syncyti
viru
coronaviru
sar
viru
rhinoviru
parainfluenza
viru
umifenovir
inhibit
variou
influenza
viru
strain
includ
rimantadin
ozeltamivirresist
variant
well
influenza
b
virus
includ
pandem
influenza
swl
virus
cultur
mdck
cell
highli
pathogen
avian
virus
rang
lung
mice
treat
umifenovir
less
sever
histopatholog
lesion
compar
control
group
umifenovir
possess
micromolarlevel
antivir
effect
valu
rang
vero
cell
infect
zika
viru
west
nile
viru
tickborn
enceph
viru
therefor
arbidol
could
promis
therapeut
agent
select
treatment
flavivir
infect
sensit
umifenovir
influenza
virus
circul
season
well
sensit
influenza
viru
isol
patient
proven
arbitr
studi
clinic
isol
influenza
virus
obtain
therapi
suscept
umifenovir
effect
concentr
rang
without
develop
drugresist
variant
experiment
studi
concentr
mgml
prove
direct
antivir
activ
umifenovir
earli
viral
replic
sever
acut
respiratori
syndrom
sar
viru
cultur
cell
umifenovir
arbidol
licens
wide
use
russia
prophylaxi
andor
treatment
influenza
clinic
trial
umifenovir
perform
former
ussr
postmarket
phase
iv
trial
influenza
season
doubleblind
random
placebocontrol
clinic
studi
arbitr
clinicaltrialsgov
identifi
investig
efficaci
safeti
arbidol
among
adult
carri
russia
umifenovir
mg
daili
five
day
significantli
p
reduc
durat
fever
h
umifenovir
group
placebo
group
muscl
pain
vs
weak
vs
umifenovirtr
group
compar
control
untreat
patient
reduc
risk
complic
name
influenza
low
respiratori
tract
infect
vs
postmarket
surveil
effici
umifenovir
clinic
use
made
retrospect
analyz
patient
influenza
arvi
hospit
region
russian
feder
patient
treat
umifenovir
first
h
diseas
onset
durat
fever
frequenc
pneumonia
prove
lower
patient
receiv
antivir
therapi
umifenovir
therapi
substanti
reduc
durat
fever
risk
complic
especi
patient
laboratoryconfirm
influenza
infect
prophylact
effect
arbidol
also
studi
random
placebocontrol
trial
children
studi
conduct
pasteur
institut
st
petersburg
includ
children
receiv
arbidol
twice
week
three
week
peak
influenza
morbid
arbidol
prophylaxi
reduc
overal
morbid
depend
age
group
durat
ill
also
decreas
day
arbidol
effect
prevent
treat
influenza
might
due
coexist
two
action
specif
antivir
activ
influenza
respiratori
virus
interferoninduc
immunemodul
properti
shown
cultur
cell
anim
human
arbidoltr
patient
lower
baselin
immun
show
improv
immunolog
paramet
number
lymphocyt
b
lymphocyt
concentr
serum
immunoglobulin
administr
singl
oral
dose
umifenovir
g
healthi
adult
volunt
result
induct
serum
interferon
interferon
unitsml
children
administr
gkgday
lead
increas
endogen
interferon
product
subject
evid
umifenovir
help
phagocyt
action
macrophag
presenc
direct
antivir
action
also
indirect
effect
reason
investig
antioxid
activ
umifenovir
free
hydroxyl
group
provid
antioxid
activ
umifenovir
figur
previous
antioxid
effect
umifenovir
prevent
lipid
peroxid
studi
vitro
author
prove
substanc
lipid
antioxid
howev
lipid
peroxid
restrict
oxid
stress
assess
antioxid
potenti
relat
rosreact
aqueou
phase
less
import
nonlipid
ro
may
caus
oxid
modif
protein
dna
studi
need
character
comprehens
antioxid
properti
umifenovir
convent
approach
base
quantit
comparison
refer
compound
assess
antioxid
capac
substanc
paramet
reflect
abil
substanc
scaveng
free
radic
exampl
trap
method
total
radicaltrap
antioxid
potenti
wide
use
base
scaveng
free
radic
form
thermolabil
azocompound
howev
method
take
physicochem
characterist
antioxid
account
anoth
strategi
base
evalu
rate
constant
interact
antioxid
radic
work
studi
antioxid
properti
umifenovir
modifi
trap
protocol
use
comput
simul
chemic
kinet
scheme
antioxid
reaction
rate
constant
propos
steadyst
product
free
radic
provid
decomposit
dihydrochlorid
abap
luminesc
decreas
background
level
almost
instantli
trolox
ad
abap
luminol
mixtur
certain
interv
latent
period
trolox
complet
exhaust
luminesc
return
sharpli
initi
level
figur
area
luminesc
depress
reflect
total
amount
scaveng
radic
linearli
depend
trolox
concentr
figur
calibr
equat
c
r
p
n
c
trolox
concentr
nm
umifenovir
chemiluminogram
anoth
type
depress
incomplet
depress
stationari
level
lower
initi
one
figur
therefor
mechan
freerad
scaveng
trolox
umifenovir
differ
accord
curv
scaveng
effect
umifenovir
involv
least
two
phase
fast
slow
area
depress
fast
part
linearli
depend
umifenovir
concentr
figur
c
r
p
n
c
umifenovir
concentr
nm
troloxequival
antioxid
capac
substanc
determin
use
trap
tar
total
antioxid
reactiv
methodolog
tar
index
obtain
instantan
decreas
luminesc
ad
antioxid
trap
index
calcul
latent
period
howev
umifenovir
method
applic
take
slow
part
scaveng
effect
account
propos
use
area
total
depress
measur
antioxid
capac
umifenovir
figur
area
depress
defin
integr
differ
blank
analyt
plot
sum
area
fast
depress
slow
depress
area
calcul
use
special
design
featur
powergraph
softwar
tabl
provid
calcul
antioxid
capac
valu
umifenovir
trolox
comput
simul
use
estim
rate
constant
antioxid
reaction
umifenovir
antioxid
activ
suppos
reaction
given
initi
concentr
reactant
rate
constant
vari
achiev
maximum
fit
calcul
experiment
plot
figur
figur
show
experiment
curv
obtain
nm
trolox
umifenovir
use
comput
simul
respect
simul
blank
stationari
level
chemiluminesc
simpl
model
consist
two
reaction
propos
reaction
free
radic
gener
chemiluminesc
reaction
abap
lum
rate
constant
kr
p
light
klum
lum
luminol
molecul
free
radic
reaction
product
excit
state
antioxid
react
p
stabl
product
freerad
reaction
simul
effect
antioxid
reaction
trolox
ad
set
p
kin
antioxid
inhibitor
two
reaction
ad
umifenovir
p
p
figur
show
calcul
data
trolox
umifenovir
figur
show
combin
calcul
experiment
plot
umifenovir
trolox
rate
constant
free
radic
scaveng
estim
kin
umifenovir
rate
constant
estim
previous
shown
effect
antioxid
chemiluminesc
kinet
describ
singl
reaction
antioxid
free
radic
p
kin
case
chemiluminesc
kinet
strongli
depend
rate
constant
kin
depend
kin
valu
chemiluminesc
system
use
antioxid
classifi
strong
medium
weak
figur
strong
antioxid
character
high
rate
constant
quench
chemiluminesc
sharpli
complet
fix
time
interv
refer
latent
period
complet
exhaust
antioxid
follow
sharp
increas
luminesc
caus
end
latent
period
return
previou
stationari
level
exampl
fig
present
simul
chemuliminogram
antioxid
kin
weak
antioxid
low
rate
constant
exampl
kin
figur
give
latent
period
instead
luminesc
decreas
slightli
effect
weak
antioxid
prolong
react
slowli
effect
medium
antioxid
kin
figur
effect
strong
weak
antioxid
addit
trolox
chemiluminesc
system
result
complet
depress
chemiluminesc
typic
strong
antioxid
figur
onestag
scheme
kin
appear
adequ
success
comput
simul
trolox
classifi
strong
antioxid
kinet
point
view
umifenovir
chemiluminesc
kinet
complic
figur
first
immedi
addit
antioxid
signific
incomplet
decreas
intens
occur
typic
antioxid
medium
strength
second
stage
slight
decreas
intens
chemiluminesc
slow
long
rise
luminesc
stationari
level
typic
weak
antioxid
thu
twostag
model
need
consist
two
consequ
antioxid
reaction
differ
rate
constant
figur
give
exampl
simul
plot
abstract
antioxid
comput
simul
confirm
twostag
mechan
antioxid
effect
umifenovir
found
rate
constant
characterist
medium
weak
antioxid
henc
kinet
point
view
umifenovir
classifi
medium
antioxid
differ
mechan
action
trolox
umifenovir
make
imposs
trap
tar
methodolog
quantif
antioxid
capac
umifenovir
measur
antioxid
capac
propos
use
total
area
depress
chemiluminesc
includ
fast
slow
part
chemiluminogram
umifenovir
correspond
maxim
concentr
blood
oral
administr
mg
troloxequival
antioxid
capac
high
henc
thermodynam
point
view
umifenovir
effect
antioxid
trolox
time
note
effect
umifenovir
last
hour
figur
effect
trolox
last
minut
thu
umifenovir
act
fivefold
longer
trolox
let
us
compar
result
data
obtain
vasil
eva
al
use
chemiluminesc
system
consist
phospholipid
liposom
coumarin
c
tri
buffer
solut
determin
antioxid
effect
umifenovir
lipid
peroxid
concentr
depress
amplitud
slow
flash
valu
two
order
magnitud
lower
author
attribut
fact
poor
solubl
umifenovir
lipid
note
comprehens
mechan
lipid
peroxid
amplitud
slow
flash
correl
antioxid
capac
complex
way
use
semiquantit
assess
measur
amplitud
fast
flash
would
adequ
possibl
chemiluminomet
use
author
base
latent
time
slow
flash
author
propos
antioxid
effect
umifenovir
due
reaction
free
radic
iron
howev
conclus
requir
confirm
comput
simul
may
aim
next
studi
studi
use
azobi
hydrochlorid
wellknown
water
solubl
radic
initi
success
appli
initi
lipid
peroxid
substanc
form
aliphat
carboncent
radic
transform
reactiv
peroxyl
radic
presenc
oxygen
consid
good
model
substanc
ozon
uvb
exposur
abap
radic
gener
offer
use
tool
studi
oxid
stress
biochem
biolog
model
antioxid
properti
substanc
due
simpl
chemic
mechan
degrad
possibl
work
physiolog
temperatur
howev
studi
perform
aqueou
phase
lipid
sum
umifenovir
potent
antioxid
effect
relat
organ
radic
aqueou
phase
due
twostag
mechan
phenomenon
make
seriou
contribut
compens
oxid
stress
caus
viral
diseas
therapeut
effect
drug
studi
therapeut
effect
umifenovir
anim
influenza
model
comparison
antioxid
potenti
special
interest
enhanc
chemiluminesc
protocol
quantifi
antioxid
activ
umifenovir
chemiluminesc
system
consist
sourc
free
radic
azobi
dihydrochlorid
abap
sigma
saint
loui
mo
usa
chemiluminesc
probe
luminol
sigma
method
describ
elsewher
luminol
solut
mm
sigma
saint
loui
mo
usa
abap
solut
mmoll
prepar
dissolv
weigh
sampl
phosphat
buffer
solut
mm
ph
sigma
saint
loui
mo
usa
total
volum
cuvett
ml
mixtur
abap
luminol
final
concentr
mm
respect
ad
buffer
solut
ph
chemiluminesc
record
stationari
level
achiev
aliquot
antioxid
solut
trolox
umifenovir
ad
registr
perform
new
steadyst
level
achiev
figur
refer
compound
trolox
sigma
saint
loui
mo
usa
watersolubl
analogu
vitamin
e
use
stock
solut
mm
trolox
prepar
phosphat
buffer
solut
work
solut
prepar
dilut
stock
solut
buffer
solut
umifenovir
erregierr
spa
san
paolo
argon
bg
itali
gmol
dissolv
aceton
panreac
castellar
del
barcelona
spain
measur
carri
chemiluminomet
disoft
moscow
russia
chemiluminomet
provid
detect
visibl
light
within
rang
nm
light
filter
use
experi
signal
process
perform
powergraph
profession
softwar
disoft
moscow
russia
statist
process
data
perform
statistica
softwar
statsoft
inc
tulsa
ok
usa
contrast
trap
tar
methodolog
determin
total
antioxid
potenti
umifenovir
calcul
total
area
depress
sum
area
depress
fast
phase
scaveng
free
radic
area
depress
slow
phase
scaveng
free
radic
shade
area
figur
area
depress
calcul
powergraph
profession
softwar
comput
simul
carri
special
design
comput
program
kinet
analyz
dyu
izmailov
set
predetermin
reaction
initi
concentr
reactant
rate
constant
select
provid
maxim
fit
experiment
calcul
plot
criterion
maxim
fit
minimum
sum
squar
residu
calcul
originpro
softwar
originlab
northampton
usa
